Research Article


DOI :10.26650/JARHS2021-939378   IUP :10.26650/JARHS2021-939378    Full Text (PDF)

Triptolide: Regulator of Cellular Metabolism of Significant Fraction of Small Cell Lung Cancer via lncRNAs

Onur TokgünKubilay İnci

Objective: Small cell lung cancer accounts for 15% of all lung cancer cases. Myc family is frequently amplified and/or overexpressed in 20% of small cell lung cancers and can promote carcinogenesis. Triptolide, a Chinese medicinal herb, is an anticancer reagent isolated from Tripterygium wilfordii Hook f. This study aimed to investigate Triptolide's possible effect on Myc overexpressed/ amplified SCLC cells. Materials and methods: To determine the expression of Myc and Myc-dependent metabolic genes, H209, H209myc, N417, and Lu135 cells were treated with Triptolide, and expression levels of Myc and associated lncRNAs were measured by qRT-PCR. Western blot analysis was performed to evaluate Myc, p21, cyclin D1 expressions. Besides, glucose uptake activity was assessed in the triptolide-treated cells. Results: We have observed that Triptolide inhibited the proliferation of SCLC cells by inhibiting MYC expression. Triptolide has been found to repress cellular proliferation, glucose metabolism, and glucose uptake, resulting in decreased Glut1, Glut4, HK2, LDHA, and Eno1. Triptolide changed the expressions of cellular proliferation and metabolism-related lncRNAs (ANRIL, PVT1, PTENP1, H19, and lincRNA-p21). Conclusion: The results have strongly indicated that triptolide treatment reduces cellular proliferation and glucose metabolism by regulating lncRNA expressions. Triptolide treatment would be a promising therapeutic strategy for SCLC.

DOI :10.26650/JARHS2021-939378   IUP :10.26650/JARHS2021-939378    Full Text (PDF)

Triptolit: Küçük Hücreli Akciğer Kanserinin Önemli Fraksiyonunun lncRNA'lar aracılı Hücresel Metabolizmasının Düzenleyicisi

Onur TokgünKubilay İnci

Amaç: Küçük hücreli akciğer kanseri (KHAK), tüm akciğer kanseri vakalarının %15'ini oluşturmaktadır. Myc ailesi, küçük hücreli akciğer kanserlerinin %20'sinde sıklıkla amplifiye/ aşırı eksprese edilir ve karsinogenezi indüklemektedir. Bir Çin şifalı bitkisi olan Triptolit, Tripterygium wilfordii Hook f 'den izole edilen bir antikanser moleküldür. Bu çalışma, Triptolit'in Myc aşırı eksprese/amplifiye KHAK hücreleri üzerindeki olası etkisini araştırmayı amaçlamıştır. Materyal ve metod: Myc ve Myc'ye bağlı metabolik genlerin ekspresyonunu belirlemek için H209, H209myc, N417 ve Lu135 hücreleri Triptolit ile muamele edildi ve Myc ve ilişkili lncRNA'ların ekspresyon seviyeleri qRT-PCR ile analiz edildi. Myc, p21, siklin D1 protein ifadelerini değerlendirmek için Western blot analizi yapıldı. Ayrıca, triptolit ile muamele edilmiş hücrelerde glikoz alınım aktivitesi ölçüldü. Bulgular: Triptolit'in MYC ekspresyonunu inhibe ederek KHAK hücrelerinin proliferasyonunu baskıladığını gözlemledik. Triptolitin hücresel proliferasyonu, glikoz metabolizmasını ve glikoz alımını inhibe ettiği ve Glut1, Glut4, HK2, LDHA ve Eno1 ifadelerinde azalmaya neden olduğu saptandı. Triptolit’in hücresel proliferasyon ve metabolizma ile ilişkili lncRNA'ların (ANRIL, PVT1, PTENP1, H19 ve lincRNA-p21) ifadelerini düzenlediği gözlemlendi. Sonuç: Sonuçlar, triptolit tedavisinin lncRNA ekspresyonlarını düzenleyerek hücresel proliferasyonu ve glikoz metabolizmasını baskıladığını güçlü bir şekilde göstermiştir. Triptolit tedavisinin KHAK için umut verici bir terapötik strateji olacağını düşünmekteyiz.


PDF View

References

  • 1. Santarpia M, Daffina MG, Karachaliou N, Gonzalez-Cao M, Lazzari C, Altavilla G, et al. Targeted drugs in small-cell lung cancer. Transl Lung Cancer Res 2016;5(1):51-70. google scholar
  • 2. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know, and the path forward. Nat Rev Cancer 2017;10:17(12):765. google scholar
  • 3. Deneka AY, Boumber Y, Beck T, Golemis EA. Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). Cancers (Basel) 2019;11(9):1297. google scholar
  • 4. Codony-Servat J, Verlicchi A, Rosell R. Cancer stem cells in small cell lung cancer. Transl Lung Cancer Res 2016;5(1):16-25. google scholar
  • 5. Taniguchi H, Sen T, Rudin CM. Targeted Therapies and Biomarkers in Small Cell Lung Cancer. Front Oncol 2020;10:741. google scholar
  • 6. Zhang W, Girard L, Zhang YA, Haruki T, Papari-Zareei M, Stastny V, et al. Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 2018;7(1):32-49. google scholar
  • 7. Lüscher B, Vervoorts J. Regulation of gene transcription by the oncoprotein MYC. Gene 2012;494(2):145-60. google scholar
  • 8. Kress TR, Sabo A, Amati B. MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer 2015;(10):593-607. google scholar
  • 9. Mollaoglu G, Guthrie MR, Böhm S, Bragelmann J, Can I, Ballieu PM et al. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell 2017;31(2):270-85. google scholar
  • 10. Garda-Gutierrez L, Bretones G, Molina E, Arechaga I, Symonds C, Acosta JC et al. Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27. Sci Rep 2019;9(1):18693. google scholar
  • 11. Schwinkendorf D, Gallant P. The conserved Myc box 2 and Myc box 3 regions are important, but not essential, for Myc function in vivo. Gene 2009;436(1-2): 90-100. google scholar
  • 12. Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res 2012;18(20):5546-53. google scholar
  • 13. Tokgun O, Tokgun PE, Inci K, Akca H. lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation. Anticancer Agents Med Chem. 2020;20(17):2074-81. google scholar
  • 14. Kim JW, Zeller KI, Wang Y, Jegga AG, Aronow BJ, O’Donnell KA, et al. Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol 2004;24(13):5923-36. google scholar
  • 15. Huarte M. The emerging role of lncRNAs in cancer. Nat Med 2015;21:1253-61. google scholar
  • 16. Tokgun PE, Tokgun O, Kurt S. MYC-driven regulation of long non-coding RNA profiles in breast cancer cells. Gene 2019;25 (714):143955. google scholar
  • 17. Dong Y, Tu R, Liu H. Regulation of cancer cell metabolism: oncogenic MYC in the driver’s seat. Sig Transduct Target Ther 2020;5(1):124. google scholar
  • 18. Dang CV. Therapeutic targeting of Myc-reprogrammed cancer cell metabolism. Cold Spring Harb Symp Quant Biol 2011;76:369-74. google scholar
  • 19. Kato F, Fiorentino FP, Alibes A, Perucho M, Sanchez-Cespedes M, Kohno T et al. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells. Oncotarget. 2016;7(47):77378-88. google scholar
  • 20. Fiorentino FP, Tokgün E, Sole-Sanchez S, Giampaolo S, Tokgün O, Jauset T, Kohno T et al. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation. Oncotarget 2016;7(21):31014-28. google scholar
  • 21. Noel P, Von Hoff DD, Saluja AK, Velagapudi M, Borazanci E, Han H. Triptolide and Its Derivatives as Cancer Therapies. Trends Pharmacol Sci 2019;40(5):327-41. google scholar
  • 22. Zhu J, Wang H, Chen F, Lv H, Xu Z, Fu J et al. Triptolide enhances chemotherapeutic efficacy of antitumor drugs in non-small-cell lung cancer cells by inhibiting Nrf2-ARE activity. Toxicol Appl Pharmacol 2018;358:1-9. google scholar
  • 23. Chen SR, Dai Y, Zhao J, Lin L, Wang Y, Wang Y. A Mechanistic Overview of Triptolide and Celastrol, Natural Products from Tripterygium wilfordii Hook F. Front Pharmacol 2018;9:104. google scholar
  • 24. Kong J, Wang L, Ren L, Yan Y, Cheng Y, Huang Z et al. Triptolide induces mitochondria-mediated apoptosis of Burkitt’s lymphoma cell via deacetylation of GSK-3^ by increased SIRT3 expression. Toxicol Appl Pharmacol 2018;342:1-13. google scholar
  • 25. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985;45(6):2913-23. google scholar
  • 26. Lu W, Cao F, Wang S, Sheng X, Ma J. LncRNAs: The Regulator of Glucose and Lipid Metabolism in Tumor Cells. Front Oncol 2019;9:1099. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Tokgün, O., & İnci, K. (2021). Triptolide: Regulator of Cellular Metabolism of Significant Fraction of Small Cell Lung Cancer via lncRNAs. Journal of Advanced Research in Health Sciences, 4(3), 95-103. https://doi.org/10.26650/JARHS2021-939378


AMA

Tokgün O, İnci K. Triptolide: Regulator of Cellular Metabolism of Significant Fraction of Small Cell Lung Cancer via lncRNAs. Journal of Advanced Research in Health Sciences. 2021;4(3):95-103. https://doi.org/10.26650/JARHS2021-939378


ABNT

Tokgün, O.; İnci, K. Triptolide: Regulator of Cellular Metabolism of Significant Fraction of Small Cell Lung Cancer via lncRNAs. Journal of Advanced Research in Health Sciences, [Publisher Location], v. 4, n. 3, p. 95-103, 2021.


Chicago: Author-Date Style

Tokgün, Onur, and Kubilay İnci. 2021. “Triptolide: Regulator of Cellular Metabolism of Significant Fraction of Small Cell Lung Cancer via lncRNAs.” Journal of Advanced Research in Health Sciences 4, no. 3: 95-103. https://doi.org/10.26650/JARHS2021-939378


Chicago: Humanities Style

Tokgün, Onur, and Kubilay İnci. Triptolide: Regulator of Cellular Metabolism of Significant Fraction of Small Cell Lung Cancer via lncRNAs.” Journal of Advanced Research in Health Sciences 4, no. 3 (Jun. 2022): 95-103. https://doi.org/10.26650/JARHS2021-939378


Harvard: Australian Style

Tokgün, O & İnci, K 2021, 'Triptolide: Regulator of Cellular Metabolism of Significant Fraction of Small Cell Lung Cancer via lncRNAs', Journal of Advanced Research in Health Sciences, vol. 4, no. 3, pp. 95-103, viewed 30 Jun. 2022, https://doi.org/10.26650/JARHS2021-939378


Harvard: Author-Date Style

Tokgün, O. and İnci, K. (2021) ‘Triptolide: Regulator of Cellular Metabolism of Significant Fraction of Small Cell Lung Cancer via lncRNAs’, Journal of Advanced Research in Health Sciences, 4(3), pp. 95-103. https://doi.org/10.26650/JARHS2021-939378 (30 Jun. 2022).


MLA

Tokgün, Onur, and Kubilay İnci. Triptolide: Regulator of Cellular Metabolism of Significant Fraction of Small Cell Lung Cancer via lncRNAs.” Journal of Advanced Research in Health Sciences, vol. 4, no. 3, 2021, pp. 95-103. [Database Container], https://doi.org/10.26650/JARHS2021-939378


Vancouver

Tokgün O, İnci K. Triptolide: Regulator of Cellular Metabolism of Significant Fraction of Small Cell Lung Cancer via lncRNAs. Journal of Advanced Research in Health Sciences [Internet]. 30 Jun. 2022 [cited 30 Jun. 2022];4(3):95-103. Available from: https://doi.org/10.26650/JARHS2021-939378 doi: 10.26650/JARHS2021-939378


ISNAD

Tokgün, Onur - İnci, Kubilay. Triptolide: Regulator of Cellular Metabolism of Significant Fraction of Small Cell Lung Cancer via lncRNAs”. Journal of Advanced Research in Health Sciences 4/3 (Jun. 2022): 95-103. https://doi.org/10.26650/JARHS2021-939378



TIMELINE


Submitted19.05.2021
Accepted11.06.2021
Published Online21.09.2021

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.